Antitumor and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma in vivo. 1996

A C Sharada, and F E Solomon, and P U Devi, and N Udupa, and K K Srinivasan
Department of Radiobiology, Kasturba Medical College, Manipal, Karnataka, India.

The antitumor and radiosensitizing effects of withaferin A (WA), a steroidal lactone from Withania somnifera, was studied on Ehrlich ascites carcinoma in vivo. The acute LD50(14) for WA in Swiss mice was approximately 80 mg/kg. Twenty-four hours after i.p. inoculation of 10(6) tumor cells, WA was injected i.p. at different dose fractions (5 or 7.5 mg/kg x 8, 10 mg/kg x 5, 20 or 30 mg/kg x 2) with or without abdominal gamma irradiation (RT, 75. Gy) after the first drug dose. Increase in life span and tumor-free survival were studied up to 120 days. The drug inhibited tumor growth and increased survival, which was dependent on the WA dose per fraction rather than the total dose. Combination of RT with all the drug schedules increased tumor cure and tumor-free survival, the best effect seen after 2 fractions of 30 mg/kg each. In another experiment WA was given as 2 (40 mg/kg x 2), 3 (30 mg/kg x 3) or 4 (20 mg/kg x 4) fractions at 5, 7 or 10 days after tumor inoculation with or without RT after the first drug dose. At 7 and 10 days after inoculation the drug was effective only at 40 mg/kg x 2, but with RT 30 mg/kg x 3 produced an equal effect (20% survival) on 7 day old tumors.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007928 Lethal Dose 50 The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population. LD50,Dose 50, Lethal
D008136 Longevity The normal length of time of an organism's life. Length of Life,Life Span,Lifespan,Life Spans,Lifespans
D008297 Male Males
D011838 Radiation-Sensitizing Agents Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. Radiation Sensitizer,Radiosensitizing Agent,Radiosensitizing Agents,Agents, Radiation-Sensitizing,Radiation Sensitizers,Radiation Sensitizing Agents,Radiation-Sensitizing Drugs,Radiation-Sensitizing Effect,Radiation-Sensitizing Effects,Radiosensitizing Drugs,Radiosensitizing Effect,Radiosensitizing Effects,Agent, Radiosensitizing,Agents, Radiation Sensitizing,Agents, Radiosensitizing,Drugs, Radiation-Sensitizing,Drugs, Radiosensitizing,Effect, Radiation-Sensitizing,Effect, Radiosensitizing,Effects, Radiation-Sensitizing,Effects, Radiosensitizing,Radiation Sensitizing Drugs,Radiation Sensitizing Effect,Radiation Sensitizing Effects,Sensitizer, Radiation,Sensitizers, Radiation,Sensitizing Agents, Radiation
D011867 Radioisotope Teletherapy A type of high-energy radiotherapy using a beam of gamma-radiation produced by a radioisotope source encapsulated within a teletherapy unit. Teleradioisotope Therapy,Teletherapy, Radioisotope,Therapy, Teleradioisotope
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002286 Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms. Ehrlich Ascites Tumor,Ascites Tumor, Ehrlich,Ehrlich Tumor Carcinoma,Tumor, Ehrlich Ascites
D003037 Cobalt Radioisotopes Unstable isotopes of cobalt that decay or disintegrate emitting radiation. Co atoms with atomic weights of 54-64, except 59, are radioactive cobalt isotopes. Radioisotopes, Cobalt

Related Publications

A C Sharada, and F E Solomon, and P U Devi, and N Udupa, and K K Srinivasan
January 1983, Radiobiologiia,
A C Sharada, and F E Solomon, and P U Devi, and N Udupa, and K K Srinivasan
October 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
A C Sharada, and F E Solomon, and P U Devi, and N Udupa, and K K Srinivasan
March 1970, International journal of cancer,
A C Sharada, and F E Solomon, and P U Devi, and N Udupa, and K K Srinivasan
August 1967, Arzneimittel-Forschung,
A C Sharada, and F E Solomon, and P U Devi, and N Udupa, and K K Srinivasan
January 1976, Neoplasma,
A C Sharada, and F E Solomon, and P U Devi, and N Udupa, and K K Srinivasan
June 2013, Toxicology and industrial health,
A C Sharada, and F E Solomon, and P U Devi, and N Udupa, and K K Srinivasan
December 1981, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
A C Sharada, and F E Solomon, and P U Devi, and N Udupa, and K K Srinivasan
January 2021, Integrative cancer therapies,
A C Sharada, and F E Solomon, and P U Devi, and N Udupa, and K K Srinivasan
November 2003, Ultrasound in medicine & biology,
A C Sharada, and F E Solomon, and P U Devi, and N Udupa, and K K Srinivasan
August 2012, Journal of ethnopharmacology,
Copied contents to your clipboard!